Skip to main content
icon for Apnimed IPO Closing Market Cap

Apnimed IPO Closing Market Cap

icon for Apnimed IPO Closing Market Cap

Apnimed IPO Closing Market Cap

$2,764 Vol.

Polymarket

$2,764 Vol.

$840M-$960M

$418 Vol.

47%

$960M+

$581 Vol.

98%

This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed priced its upsized IPO at $16 per share on July 30, 2026, raising $192 million gross before fees, with shares beginning Nasdaq trading under APMD on July 31. The offering exceeded the initial $160 million target amid robust demand from long-only investors, pushing early trading prices to the $20–$25 range and implying a market capitalization well above the $570–$680 million valuation at pricing. This momentum, fueled by the company’s late-stage oral sleep apnea candidate and a favorable 2026 biotech IPO environment, underpins the 75% implied probability for a closing market cap above $960 million and 44% for the $840–960 million band. Key near-term catalysts include the August 3 offering close and any exercise of the 1.8 million share overallotment option.

This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$2,764
Tanggal Berakhir
Jul 31, 2026
Pasar Dibuka
Jul 29, 2026, 6:20 PM ET
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed priced its upsized IPO at $16 per share on July 30, 2026, raising $192 million gross before fees, with shares beginning Nasdaq trading under APMD on July 31. The offering exceeded the initial $160 million target amid robust demand from long-only investors, pushing early trading prices to the $20–$25 range and implying a market capitalization well above the $570–$680 million valuation at pricing. This momentum, fueled by the company’s late-stage oral sleep apnea candidate and a favorable 2026 biotech IPO environment, underpins the 75% implied probability for a closing market cap above $960 million and 44% for the $840–960 million band. Key near-term catalysts include the August 3 offering close and any exercise of the 1.8 million share overallotment option.

This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$2,764
Tanggal Berakhir
Jul 31, 2026
Pasar Dibuka
Jul 29, 2026, 6:20 PM ET
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

Hati-hati dengan link eksternal.

Pertanyaan yang Sering Diajukan

"Apnimed IPO Closing Market Cap" adalah pasar prediksi di Polymarket dengan 7 hasil yang mungkin di mana trader membeli dan menjual saham berdasarkan apa yang mereka yakini akan terjadi. Hasil terdepan saat ini adalah "$960M+" di 75%, diikuti oleh "$840M-$960M" di 47%. Harga mencerminkan probabilitas crowd-sourced real-time. Misalnya, saham yang dihargai 75¢ menyiratkan bahwa pasar secara kolektif memberikan peluang 75% pada hasil tersebut. Peluang ini bergeser terus-menerus saat trader bereaksi terhadap perkembangan dan informasi baru. Saham dengan hasil yang benar bisa ditukarkan seharga $1 setiap saham saat pasar diselesaikan.

"Apnimed IPO Closing Market Cap" adalah pasar yang baru dibuat di Polymarket, diluncurkan pada Jul 29, 2026. Sebagai pasar awal, ini adalah kesempatanmu untuk menjadi salah satu trader pertama yang menetapkan peluang dan membangun sinyal harga awal pasar. Kamu juga bisa menandai halaman ini untuk melacak volume dan aktivitas trading seiring pasar mendapatkan traksi.

Untuk trading di "Apnimed IPO Closing Market Cap," jelajahi 7 hasil yang tersedia di halaman ini. Setiap hasil menampilkan harga saat ini yang mewakili probabilitas tersirat pasar. Untuk mengambil posisi, pilih hasil yang menurutmu paling mungkin, pilih "Ya" untuk mendukungnya atau "Tidak" untuk menentangnya, masukkan jumlahmu, dan klik "Trade." Jika hasil pilihanmu benar saat pasar diselesaikan, saham "Ya" kamu membayar $1 masing-masing. Jika salah, mereka membayar $0. Kamu juga bisa menjual sahammu kapan saja sebelum resolusi jika kamu ingin mengamankan keuntungan atau memotong kerugian.

Unggulan saat ini untuk "Apnimed IPO Closing Market Cap" adalah "$960M+" di 75%, yang berarti pasar memberikan peluang 75% pada hasil tersebut. Hasil terdekat berikutnya adalah "$840M-$960M" di 47%. Peluang ini diperbarui secara real-time saat trader membeli dan menjual saham, sehingga mencerminkan pandangan kolektif terbaru tentang apa yang paling mungkin terjadi. Cek kembali secara rutin atau tandai halaman ini untuk mengikuti bagaimana peluang bergeser saat informasi baru muncul.

Aturan resolusi untuk "Apnimed IPO Closing Market Cap" mendefinisikan dengan tepat apa yang harus terjadi agar setiap hasil dinyatakan sebagai pemenang — termasuk sumber data resmi yang digunakan untuk menentukan hasilnya. Kamu bisa meninjau kriteria resolusi lengkap di bagian "Aturan" di halaman ini di atas komentar. Kami menyarankan membaca aturan dengan cermat sebelum trading, karena mereka menentukan kondisi tepat, kasus khusus, dan sumber yang mengatur bagaimana pasar ini diselesaikan.